| Literature DB >> 33538258 |
Richard L Weinberg1, Robert D Brook2, Melvyn Rubenfire3, Kim A Eagle4.
Abstract
Omega-3 polyunsaturated fatty acids (PUFAs) are a key component of a heart-healthy diet. For patients without clinical atherosclerotic cardiovascular disease, 2 or more servings of fatty fish per week is recommended to obtain adequate intake of omega-3 PUFAs. If this not possible, dietary supplementation with an appropriate fish oil may be reasonable. Supplementation with omega-3 PUFA capsules serves 2 distinct but overlapping roles: treatment of hypertriglyceridemia and prevention of cardiovascular events. Marine-derived omega-3 PUFAs reduce triglycerides and have pleiotropic effects including decreasing inflammation, improving plaque composition and stability, and altering cellular membranes. Clinical trial data have shown inconsistent results with omega-3 PUFAs improving cardiovascular outcomes. In this paper, the authors provide an overview of PUFAs and a summary of key clinical trial data. Recent trial data suggest the use of prescription eicosapentaenoic acid ethyl ester for atherosclerotic cardiovascular disease event reduction in selected populations.Entities:
Keywords: docosahexaenoic acid; eicosapentaenoic acid; fish oil; omega-3 fatty acids
Year: 2021 PMID: 33538258 DOI: 10.1016/j.jacc.2020.11.060
Source DB: PubMed Journal: J Am Coll Cardiol ISSN: 0735-1097 Impact factor: 24.094